Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Central China Normal Univ. WDR5 compound Ac7
- Development stage
- Preclinical
- Lead developer
- Central China Normal University
- Modality
- Peptides
01
Overview
Central China Normal Univ. WDR5 compound Ac7: sourced facts only. name: "Structure-guided optimization led to the development of EMBOW-derived peptides, notably Ac7, which exhibited high affinity for WDR5 (Kd = 9.17 ± 4.01 nM)." [PMID:41135522]; target: "Structure-guided optimization led to the development of EMBOW-derived peptides, notably Ac7, which exhibited high affinity for WDR5 (Kd = 9.17 ± 4.01 nM)." [PMID:41135522]; developer: "Laboratory of Pesticides and Chemistry Key Laboratory of Ministry of Education, School of Life Sciences, Central China Normal University, Wuhan, Hubei, P.R. China; Hubei Key Laboratory of Genetic Regulation and Integrative Biology, School of Life Sciences, Central China Normal University, Wuhan, Hubei, P.R. China." [PMID:41135522]; modality: "Structure-guided optimization led to the development of EMBOW-derived peptides, notably Ac7, which exhibited high affinity for WDR5 (Kd = 9.17 ± 4.01 nM)." [PMID:41135522]; stage: "Importantly, in xenograft mouse models, Ac7 demonstrated significant anti-tumor activity with low toxicity." [PMID:41135522]
02
Targets
WDR5 (WD repeat-containing protein 5)
Beyond the preview
Go deeper on Central China Normal Univ. WDR5 compound Ac7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Central China Normal Univ. WDR5 compound Ac7.